Skip to content
Open access

Effects of carnosic acid on renal injury-related parameters and iNOS immunoreactivity in an experimental model of contrast-associated acute kidney injury

Aug 2026 · Renal Failure · Vol 48 · 0 citations · 20 references
Medicine

Abstract

Abstract Contrast-associated acute kidney injury (CA-AKI) remains a clinically relevant complication of iodinated contrast exposure. Carnosic acid possesses antioxidant and anti-inflammatory properties, but its effects on renal biochemical injury, tubular damage, and inducible nitric oxide synthase (iNOS) immunoreactivity in CA-AKI remain unclear. This study evaluated carnosic acid in an experimental rat model of CA-AKI. Twenty-four adult male rats were randomly assigned to control, CA-AKI, or CA-AKI plus carnosic acid groups (n = 8 each). CA-AKI was induced by 24-h restriction, furosemide, and intravenous iohexol. After contrast exposure, carnosic acid was administered therapeutically at 30 mg/kg once daily for 5 days through an orogastric catheter. Serum urea, creatinine, sodium, potassium, and creatine kinase levels were measured. Tubular injury was scored semi-quantitatively, and iNOS immunoreactivity was assessed using the H-score. Groups were compared using the Kruskal–Wallis test with Dunn–Bonferroni post hoc analysis. Compared with controls, the CA-AKI group had significantly higher urea, creatinine, potassium, creatine kinase, tubular injury scores, and iNOS H-scores and lower sodium levels. Compared with untreated CA-AKI, carnosic acid treatment significantly reduced urea and creatine kinase levels and increased sodium levels. Creatinine concentrations, tubular injury scores, and iNOS H-scores were numerically lower after treatment, but pairwise differences were not statistically significant. Thus, carnosic acid improved selected biochemical parameters, while its apparent histopathological and iNOS-related effects remained inconclusive. These findings support a possible but limited protective effect in this experimental setting. Further studies incorporating molecular validation and dose and timing protocols are required to clarify its renoprotective potential and mechanisms.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.